| 2020 |
Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF. Zoledronate. Bone. August 2020;137:115390. |
4 |
3 |
| 2020 |
Center JR, Lyles KW, Bliuc D. Bisphosphonates and lifespan. Bone. December 2020;141:115566. |
4 |
4 |
| 2020 |
Ogunwale AN, Colon‐Emeric CS, Sloane R, Adler RA, Lyles KW, Lee RH. Acetylcholinesterase inhibitors are associated with reduced fracture risk among older veterans with dementia. J Bone Miner Res. March 2020;35(3):440-445. |
1 |
1 |
| 2007 |
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. NEJM. November 1, 2007;357(18):1799-1809. |
82 |
79 |
| 2021 |
Sagalla N, Colón-Emeric C, Sloane R, Lyles K, Vognsen J, Lee R. FRAX without BMD can be used to risk-stratify veterans who recently sustained a low trauma non-vertebral/non-hip fracture. Osteoporos Int. March 2021;32(3):467-472. |
0 |
0 |